Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

ONCOTRACK

Financiado

OncoTrack - Methods for systematic next generation oncology biomarker developmen...

We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. De... ver más

31/12/2016

BAYER

31M€

Presupuesto del proyecto: 31M€

Líder del proyecto

Bayer Pharma AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 19 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2016-12-31

0% 100%

19 Participantes

BAYER

Lider

FUNDACIO PRIVADA INSTITUT D'...

N.D. | Participante

Pfizer RD UK Limited

N.D. | Participante

MEDICAL UNIVERSITY OF GRAZ

N.D. | Participante

Proyectos interesantes

EQC2018-004733-P ADQUISIÓN DE EQUIPO PARA IDENTIFICACIÓN Y RECUPERACIÓN DE CÉ... 171K€ Cerrado

MultiCloneSeq Single-Clone Multi-omics Sequencing for Cancer Diagnosis 150K€ Cerrado

EpiCblood Towards early cancer detection and tumor classification usin... 1M€ Cerrado

ProstOmics Tissue is the issue a multi omics approach to improve pro... 2M€ Cerrado

EQC2018-005144-P Plataforma de genómica para secuenciación de célula única y... 168K€ Cerrado

FPSA13-1E-2048 Integrando la Medicina de Precisión a Nivel de la Célula Ind... 1K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 71 meses Fecha Inicio: 2011-01-01
Fecha Fin: 2016-12-31

Líder del proyecto

Bayer Pharma AG

TRL 4-5

Presupuesto del proyecto 31M€

Descripción del proyecto We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same patients. This will be complemented by the development and application of highly sensitive techniques to identify individual mutations, transcripts and proteins/protein complexes both in-situ in pathology slides as well as in patients’ blood or serum. The integration of these results will allow us to address the heterogeneity of the tumor samples, to deduce the genome/epigenome/transcriptome of the different cell types making up or originating from the tumor (e.g. circulating tumor cells, tumour stem cells or xenografts), to establish models able to predict suitable candidates for further biomarker development, and also to predict the effects and side effects of drugs in the treatment of genetically defined groups of patients. Available biomarkers, as well as biomarkers predicted from the work within the project will be validated in patient derived xenograft models and stem cell cultures, and ultimately transferred into a point of care (POC) diagnostic format. In parallel we will explore the use of the global genome and methylome information, e.g. derived from the analysis of free tumor DNA in the serum of the patient, as the ‘ultimate’ biomarker, to model the biology of the tumor (possibly even before any tumor has been localised), and as an independent route to predict clinically relevant parameters. Though sequencing/methylation analysis of the genome of the tumor through free DNA is currently still too costly for use as a routine diagnostic, this is likely to change over the period covered by the grant, due to the extremely rapid progress in the development of large scale sequencing techniques.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores